175021-11-1

Basic information

• Product Name: (3,3-dimethoxycyclobutyl)methanol
• Synonyms: (3,3-dimethoxycyclobutyl)methanol;3,3-Dimethoxycyclobutanemethanol
• CAS NO: 175021-11-1
• Molecular Formula: C₇H₁₄O₃
• Molecular Weight: 146.19
• Product Categories: API intermediates
• Mol File: 175021-11-1.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 190℃
• Flash Point: 69℃
• Appearance: /
• Density: 1.06
• Vapor Pressure: 0.151mmHg at 25°C
• Refractive Index: 1.458
• CAS DataBase Reference: (3,3-dimethoxycyclobutyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (3,3-dimethoxycyclobutyl)methanol(175021-11-1)
• EPA Substance Registry System: (3,3-dimethoxycyclobutyl)methanol(175021-11-1)

Safety Data

• Hazardous Substances Data: 175021-11-1(Hazardous Substances Data)

Usage

General Description

(3,3-dimethoxycyclobutyl)methanol is a chemical compound with the formula C9H18O3. It is a colorless liquid with a molecular weight of 174.24 g/mol. The molecule contains a cyclobutyl ring with two methoxy groups and a hydroxyl group attached to it. (3,3-dimethoxycyclobutyl)methanol is often used in organic synthesis and as a reagent in chemical reactions. It can also be used in the pharmaceutical industry as a building block for the synthesis of various drug molecules. Due to its unique structure and reactivity, (3,3-dimethoxycyclobutyl)methanol has potential applications in the field of medicinal chemistry and drug discovery. Its specific properties and uses make it an important compound in the chemical industry.

InChI:InChI=1/C7H14O3/c1-9-7(10-2)3-6(4-7)5-8/h6,8H,3-5H2,1-2H3

Upstream product

• 98231-07-3 3,3-dimethoxycyclobutanecarboxylic acid methyl ester 
• 545882-50-6 2-[(benzyloxy)methyl]-5,8-dioxaspiro[3.4]octane 
• 172324-66-2 3-(benzyloxymethyl)-2,2-dichlorocyclobutanone 
• 172324-67-3 3-benzyloxymethyl-cyclobutanone 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 695-95-4 methyl 3-oxocyclobutanecarboxylate 

Downstream Products

• 175021-12-2 (3,3-dimethoxycyclobutyl)methyl p-toluenesulfonate 
• 1003013-83-9 3-iodomethyl-1,1-dimethoxy-cyclobutane 
• 1027645-59-5 3-Chloromethyl-1,1-dimethoxy-cyclobutane 
• 175021-13-3 3-(chloromethyl)cyclobutan-1-one 
• 175021-15-5 N-<3-(chloromethyl)-1-cyclobutylidene>cyclohexylamine 
• 175021-19-9 2-isopropyl-2-azabicyclo[2.1.1]hexane 
• 583830-08-4 {[(3,3-dimethoxycyclobutyl)methoxy]methyl}benzene 
• 861252-52-0 {cis-3-[4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutyl}methyl 4-methylbenzenesulfonate 
• 861252-53-1 {trans-3-[4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutyl}methyl 4-methylbenzenesulfonate 
• 861252-61-1 {trans-3-[4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutyl}-methanol 
• 861252-06-4 cis-3-[(benzyloxy)methyl]-1-[4-(pyrrolidin-1-ylmethyl)phenyl]-cyclobutanol 
• 172324-67-3 3-benzyloxymethyl-cyclobutanone 
• 929911-61-5 (3-hydroxycyclobutyl)methyl benzoate 
• 346425-59-0 (3-oxo-cyclobutyl)methyl benzoate 

Relevant articles and documents

CYCLOALKYLIDENE CARBOXYLIC ACIDS AND DERIVATIVES AS BTK INHIBITORS

The present invention relates to novel cycloalkylidene carboxylic acids and derivatives thereof useful as Bruton tyrosine kinase (BTK) inhibitors. The present disclosure also relates to processes for their preparation, pharmaceutical compositions containing one or more such compounds, and to the use of such compounds and pharmaceutical compositions for the treatment of disorders involving mediation of BTK in humans (Formula I).

Containing cyclobutane substituent of pyrazines, its composition and use thereof

The invention relates to a cyclobutane substituent group-containing pyrazine compound and application thereof as a drug, and particularly relates to application of the cyclobutane substituent group-containing pyrazine compound in preparing the drug for preventing and treating various influenza viruses. Especially, the invention relates to a compound as shown in a general formula (I) or a stereomer, a geometrical isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and various variables are defined in the specification. The invention also relates to application of the compound as shown in the general formula (I) or the stereomer, geometrical isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof as the drug, and particularly relates to application of the compound as shown in the general formula (I) or the stereomer, geometrical isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof as the drug for preventing and treating the influenza viruses.

Substituted purine neuraminidase inhibitor and method of use thereof, and use thereof

The invention provides novel substituted purine compounds or stereoisomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof. The substituted purine compounds are used for inhibiting neuraminidase. The invention also provides a drug composition comprising the compounds, and a method for preventing or treating virus infectious diseases by using the compounds or the drug composition.